We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

CerTest VIASURE HLA Celiac RT PCR Kit Enables Rapid Resolution of HLA Haplotypes Associated with Celiac Disease

By LabMedica International staff writers
Posted on 21 Sep 2021
Print article
VIASURE HLA Celiac Real Time PCR Detection Kit
VIASURE HLA Celiac Real Time PCR Detection Kit
CerTest Biotec (Zaragoza, Spain) has developed a simple and ready to use real-time PCR for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens associated with Celiac disease (CD).

CD is an autoimmune disorder triggered by the ingestion of gluten in genetically susceptible individuals. Once thought to be a rare disease, CD diagnoses are increasing with current worldwide prevalence at 1%, with female predominance. The disease can occur at any age, with two peaks of onset - one shortly after weaning with gluten in the first two years of life, and the other in the second or third decades of life with a variety of symptoms/manifestations. This multifaceted clinical presentation leads to several phenotypes, i.e., gastrointestinal, extraintestinal, subclinical, potential, seronegative, non-responsive, and refractory.

As with any other autoimmune disease, CD has a strong hereditary component as testified by its high familial recurrence (~ 10–15%). Genetic susceptibility is associated with two sets of alleles, DQA105 - DQB102 and DQA103 - DQB103:02, which code for class II MHC DQ2 and DQ8 molecules, respectively. Although HLA-DQ2/HLA-DQ8 is frequent among the general population (25-35%), only the 3% of these HLA-compatible individuals will go on to develop CD. Being able to quickly and efficiently determine the status of the DQA and DQB alleles in potential CD patients or risk population could dramatically aide in diagnostic work-ups.

An early diagnosis could prevent the development of a clinically severe CD and for this, an exact individual genetic risk assessment could improve current diagnostic strategies and thus prognosis. Sensitive and specific serological tests have become gradually more important in the diagnostic work-up of CD although duodenal biopsy remains the diagnostic ‘gold standard’. To avoid performing this invasive technique, especially in children with symptoms suggestive of CD with high antibody titers, it has been proposed to replace it with genotyping. In a non-invasive way, identifying and quantifying the risk of developing CD in newborns from affected family members could be useful for programming individualized follow-up timing.

With the aim of contributing to the development of practical algorithm for the diagnosis of CD, CerTest has developed VIASURE HLA Celiac Real Time PCR Detection Kit for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens associated with CD. The kit detects the alleles DQA105, DQB10302, DQB102, DQA102, DQA103 and NO DQB102 in blood samples. DNA is extracted from blood specimens, multiplied using Real Time amplification and detected using specific primers and a fluorescent reporter dye probe for HLA alleles.

Using whole blood clinical samples of patients predisposed to CD, the clinical performance of VIASURE HLA Celiac Real Time PCR Detection Kit was evaluated, verifying that the test is as accurate, sensitive and specific as the assays with similar characteristics already available on the market. Notably, thanks to the product's design and its lyophilized format, handling is minimal and easier than similar molecular assays. These characteristics help the process to be faster, being able to obtain the results and therefore, the clinical diagnosis time in approximately two hours.

Related Links:

CerTest Biotec

New
Gold Supplier
Fully Automated Batch Immunoanalyzer
Evidence+
New
Flu A/B Antibodies and Antigens
HyTest Flu A/B Antibodies and Antigens
New
Cytology Sample Processor
SDSCP9000 CytoPath Processor
New
6-Channel Viscoelastometry Analyzer
ClotPro

Print article

Channels

Molecular Diagnostics

view channel
Image: A cancer cell during cell division (Photo courtesy of [U.S.] National Institutes of Health)

New Method Promises Rapid Isolation of Biomarker-Rich Extracellular Vesicles

A new method for isolating and analyzing cancer biomarkers from extracellular vesicles present in biological fluids is based on a novel magnetic particle based liquid biopsy chip. Extracellular vesicles... Read more

Microbiology

view channel
Image: Colored Transmission electron micrograph of Clostridium difficile bacterium forming an endospore (lower right, red oval). Clostridium difficile produce a toxin that irritates the colon and causes diarrhea (Photo courtesy of Kari Lounatmaa, PhD)

Quantity of Toxin in Stool Correlates with C. difficile Severity

Clostridioides difficile (syn. Clostridium difficile), also known as C. difficile, or C. diff are Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous... Read more

Technology

view channel
Image: Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk (Photo courtesy of Veracyte, Inc.)

Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk

A novel, non-invasive nasal swab test could support more timely and accurate lung nodule diagnosis. Veracyte, Inc. (South San Francisco, CA, USA) has announced that new expanded clinical validation data... Read more

Industry

view channel
Image: VSE Cat. No. 84800 with optional mobile table and phenolic work surface (Photo courtesy of HEMCO Corporation)

Hemco Offers VSE Balance Enclosure for Critical Procedures Involving Powders and Liquids

HEMCO Corporation (Independence, MO, USA) is offering its Vented Safety Enclosure (VSE) in 24-, 36- and 48-inch widths to accommodate an analytical balance and other small-scale lab processes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.